Press Releases May 1, 2026 04:05 PM

Heidmar Announces Filing of Its 2025 Annual Report on Form 20-F

Heidmar Maritime Holdings Corp. Files 2025 Annual Report on Form 20-F with SEC

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
HMR

Heidmar Maritime Holdings Corp., a Cincinnati-based company specializing in commercial and pool management of crude and product tankers, announced the filing of its annual report for fiscal year 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The report is now available electronically on Heidmar's website, with hard copies available upon request. Heidmar operates globally in key maritime hubs and focuses on providing comprehensive maritime services in the crude oil, refined petroleum products, and dry bulk shipping sectors.

Heidmar Announces Filing of Its 2025 Annual Report on Form 20-F
HMR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Heidmar filed its 2025 Annual Report (Form 20-F) with the SEC, ensuring regulatory compliance and transparency for investors.
  • The company operates in multiple global locations including Athens, London, Singapore, Chennai, Hong Kong, and Dubai, servicing crude oil, refined petroleum products, and dry bulk shipping markets.
  • Heidmar’s business model positions it as a one-stop maritime service provider, aiming to maximize customers’ profitability and provide seamless transportation services.

ATHENS and NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Heidmar Maritime Holdings Corp. (the "Company" or "Heidmar") (NASDAQ: HMR), today announced that it has filed its 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the “SEC”).

An electronic copy of the filing will be accessible on Heidmar's website under Investor Relations – Financials and Presentation.

Shareholders may also obtain a complimentary hard copy of the 2025 Annual Report on Form 20-F upon request by contacting Capital Link using the details listed at the end of this press release.

About Heidmar, Inc.

Heidmar is an Athens based, commercial and pool management business servicing the crude and product tanker market and is committed to safety, performance, relationships and transparency. With operations in Athens, London, Singapore, Chennai, Hong Kong and Dubai, Heidmar has a reputation as a reliable and responsible partner with a goal of maximizing our customers' profitability. Heidmar seeks to offer vessel owners a "one stop" solution for all maritime services in the crude oil, refined petroleum products and dry bulk shipping sectors. Heidmar believes its unique business model and extensive experience in the maritime industry allows the Company to achieve premier market coverage and utilization, as well as provide customers in the sector with seamless commercial transportation services. For more information, please visit www.heidmar.com.

CONTACT INFORMATION:

Investor Relations/Media Contact:

Nicolas Bornozis / Daniela Guerrero
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, N.Y. 10169
Tel.: (212) 661-7566
Email: heidmar@capitallink.com


Risks

  • Potential market fluctuations in the crude oil, refined petroleum, and dry bulk shipping sectors could affect Heidmar's business performance.
  • Dependence on global maritime transport demand, which can be impacted by geopolitical or economic instability, may introduce operational uncertainties.
  • Regulatory changes affecting shipping and maritime operations could impose additional costs or constraints.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026